- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Four Pillars of Heart Failure Therapy
Therapy strategies in the management of heart failure are discussed.
EP: 1.Identifying Key Risk Factors for Heart Failure
EP: 2.Socioeconomic Factors Impacting Development of Cardiac Disease
EP: 3.Distinguishing Between Heart Failure Classifications
EP: 4.Staging Heart Failure and the Importance of Early Diagnosis
EP: 5.The Role of the Primary Care Physician in Heart Failure Management
EP: 6.Four Pillars of Heart Failure Therapy
EP: 7.Selecting Optimal First-line Therapy for Patients Diagnosed with Heart Failure
EP: 8.Key Takeaways From Heart Failure Clinical Trials
EP: 9.Navigating the Patient Journey Through Heart Failure Diagnosis
EP: 10.Strategies for Treating Preserved Ejection Fraction (HFpEF)
EP: 11.Treatment Optimization Challenges Associated With Heart Failure
EP: 12.Financial Barriers Impeding Optimal Heart Failure Treatment
EP: 13.Trajectory of Heart Failure Treatment Strategies
EP: 14.Key Takeaways from Experts in Heart Failure Management
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. Axsom, MD, outlines the 4 pillars of guideline-directed medical therapy for symptomatic heart failure with reduced ejection fraction (HFrEF), which also applies to midrange ejection fraction (EF): angiotensin receptor-neprilysin inhibitors, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs); evidence-based beta blockers (metoprolol succinate, bisoprolol, carvedilol); mineralocorticoid receptor antagonists (MRAs; spironolactone, eplerenone); and sodium-glucose cotransporter-2 (SGLT2) inhibitors (dapagliflozin, empagliflozin). The specific beta blockers reduce 1-year mortality by 36% based on randomized controlled trial data. For heart failure with preserved ejection fraction (HFpEF), treatment focuses on managing comorbidities until EF declines below 60% to 65%. Implementation and adherence to guideline-directed medical therapy remains a challenge. The classification system helps guide evidence-based treatments for HFrEF, while HFpEF management is more limited but evolving.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
